Ramucirumab plus paclitaxel or FOLFIRI in platinum-refractory advanced or metastatic gastric or gastroesophageal junction adenocarcinoma-experience at two centres.
FLOT
FOLFIRI
Gastric cancer
paclitaxel
ramucirumab
Journal
Journal of gastrointestinal oncology
ISSN: 2078-6891
Titre abrégé: J Gastrointest Oncol
Pays: China
ID NLM: 101557751
Informations de publication
Date de publication:
Apr 2020
Apr 2020
Historique:
entrez:
14
5
2020
pubmed:
14
5
2020
medline:
14
5
2020
Statut:
ppublish
Résumé
Ramucirumab is a VEGFR-2 antibody that has proven to prolong overall survival (OS) in patients with pretreated metastatic gastric/gastrooesophageal junction (GEJ) adenocarcinoma. We present data from patients treated with ramucirumab and paclitaxel or FOLFIRI after failure of at least one platinum- and 5-FU-containing chemotherapy (CHT) regimen. In this retrospective two-center study, 56 patients with metastatic gastric cancer (47%) or adenocarcinoma of the GEJ (53%) were treated with paclitaxel and ramucirumab (n=38) as second-line (75%) or beyond second-line (25%) therapy. FOLFIRI-ramucirumab (FOLFIRI-R) (n=16) was given to patients with a short interval between taxane-based perioperative CHT and occurrence of metastatic disease or to those ineligible for paclitaxel. The median progression-free survival (PFS) and OS for patients treated with paclitaxel-ramucirumab (pacl-R) were 2.9 (95% CI: 2.3-3.6) and 4.4 (4.1-4.7) months, respectively, and those for patients treated with FOLFIRI-R were 5.9 (95% CI: 0.35-11.4) and 8.3 (6.6-10) months, respectively (P=0.05). We observed a trend towards prolonged PFS after perioperative taxane-based FLOT CHT (n=12) with FOLFIRI-R compared with pacl-R. Adverse events were manageable, with neutropenia and polyneuropathy (PNP) being the most common events. More than two treatment lines were given to 48.2% of patients. The use of ramucirumab in combination with FOLFIRI showed favourable PFS and OS in patients with prior treatments with platinum and/or taxane-based agents and allows further treatment lines after progression. In patients with taxane pretreatment or persistent high-grade PNP, the combination of FOLFIRI-R might be a promising combination.
Sections du résumé
BACKGROUND
BACKGROUND
Ramucirumab is a VEGFR-2 antibody that has proven to prolong overall survival (OS) in patients with pretreated metastatic gastric/gastrooesophageal junction (GEJ) adenocarcinoma. We present data from patients treated with ramucirumab and paclitaxel or FOLFIRI after failure of at least one platinum- and 5-FU-containing chemotherapy (CHT) regimen.
METHODS
METHODS
In this retrospective two-center study, 56 patients with metastatic gastric cancer (47%) or adenocarcinoma of the GEJ (53%) were treated with paclitaxel and ramucirumab (n=38) as second-line (75%) or beyond second-line (25%) therapy. FOLFIRI-ramucirumab (FOLFIRI-R) (n=16) was given to patients with a short interval between taxane-based perioperative CHT and occurrence of metastatic disease or to those ineligible for paclitaxel.
RESULTS
RESULTS
The median progression-free survival (PFS) and OS for patients treated with paclitaxel-ramucirumab (pacl-R) were 2.9 (95% CI: 2.3-3.6) and 4.4 (4.1-4.7) months, respectively, and those for patients treated with FOLFIRI-R were 5.9 (95% CI: 0.35-11.4) and 8.3 (6.6-10) months, respectively (P=0.05). We observed a trend towards prolonged PFS after perioperative taxane-based FLOT CHT (n=12) with FOLFIRI-R compared with pacl-R. Adverse events were manageable, with neutropenia and polyneuropathy (PNP) being the most common events. More than two treatment lines were given to 48.2% of patients.
CONCLUSIONS
CONCLUSIONS
The use of ramucirumab in combination with FOLFIRI showed favourable PFS and OS in patients with prior treatments with platinum and/or taxane-based agents and allows further treatment lines after progression. In patients with taxane pretreatment or persistent high-grade PNP, the combination of FOLFIRI-R might be a promising combination.
Identifiants
pubmed: 32399277
doi: 10.21037/jgo.2020.03.10
pii: jgo-11-02-366
pmc: PMC7212104
doi:
Types de publication
Journal Article
Langues
eng
Pagination
366-375Commentaires et corrections
Type : CommentIn
Informations de copyright
2020 Journal of Gastrointestinal Oncology. All rights reserved.
Déclaration de conflit d'intérêts
Conflicts of Interest: All authors have completed the ICMJE uniform disclosure form (available at http://dx.doi.org/10.21037/jgo.2020.03.10). The authors have no conflicts of interest to declare.
Références
Lancet. 2010 Aug 28;376(9742):687-97
pubmed: 20728210
Target Oncol. 2018 Apr;13(2):227-234
pubmed: 29582224
Gastric Cancer. 2018 Jan;21(1):106-113
pubmed: 28667466
J Clin Oncol. 2011 Mar 1;29(7):868-74
pubmed: 21189380
J Clin Oncol. 2012 May 1;30(13):1513-8
pubmed: 22412140
J Am Coll Surg. 2008 Feb;206(2):306-10
pubmed: 18222384
Lancet Oncol. 2014 Jan;15(1):78-86
pubmed: 24332238
Gastric Cancer. 2015 Jan;18(1):168-76
pubmed: 24557418
BMC Cancer. 2016 Aug 31;16:699
pubmed: 27582078
Lancet Oncol. 2014 Oct;15(11):1224-35
pubmed: 25240821
Eur J Cancer. 2011 Jul;47(10):1511-20
pubmed: 21561763
Gastric Cancer. 2018 Sep;21(5):819-830
pubmed: 29427038
J Gastric Cancer. 2017 Jun;17(2):132-144
pubmed: 28680718
Eur J Cancer. 2009 Jan;45(2):228-47
pubmed: 19097774
Technol Cancer Res Treat. 2018 Jan 1;17:1533034617753810
pubmed: 29390928
Cancer. 1996 Mar 1;77(5):858-63
pubmed: 8608475
J Clin Oncol. 2013 Dec 10;31(35):4438-44
pubmed: 24190112
Eur J Cancer. 2011 Oct;47(15):2306-14
pubmed: 21742485
Lancet Oncol. 2017 Mar;18(3):357-370
pubmed: 28163000
J Clin Oncol. 2016 May 1;34(13):1448-54
pubmed: 26884585
Lancet. 2014 Jan 4;383(9911):31-39
pubmed: 24094768
J Clin Oncol. 2017 May 20;35(15):1686-1694
pubmed: 28375786
Oncologist. 2019 Apr;24(4):475-482
pubmed: 30470690
Lancet Oncol. 2015 May;16(5):499-508
pubmed: 25877855
J Clin Oncol. 2016 Aug 10;34(23):2728-35
pubmed: 27325864
J Clin Oncol. 2006 May 10;24(14):2137-50
pubmed: 16682732
Ann Surg Oncol. 2006 Jan;13(1):12-30
pubmed: 16378161
N Engl J Med. 2006 Jul 6;355(1):11-20
pubmed: 16822992
Gastric Cancer. 2018 Sep;21(5):831-844
pubmed: 29397460
J Clin Oncol. 2011 Oct 20;29(30):3968-76
pubmed: 21844504
Gastric Cancer. 2018 Nov;21(6):1041-1049
pubmed: 29508095
J Clin Oncol. 2014 Nov 1;32(31):3520-6
pubmed: 25287828
Lancet. 2019 May 11;393(10184):1948-1957
pubmed: 30982686
Cancer Chemother Pharmacol. 2018 Nov;82(5):839-845
pubmed: 30167847
J Natl Cancer Inst. 2018 Jun 1;110(6):549-550
pubmed: 29361121